AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7316247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Phenylpropanolamine (combined)
Number of subjects: 0
Study 31274113 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG) usage
Number of subjects: 48
Study 31274113 — intervention group
Group type: EXPERIMENTAL
Intervention: Active users contributing with posts or comments
Number of subjects: 48
Study 31274113 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic characteristics
Number of subjects: 48
Study 28124631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided drainage
Number of subjects: 60
Study 28124631 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 60
Study 25317504 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Number of subjects: 29
Study 25317504 — intervention group
Group type: COMPARATOR
Intervention: Traditional trunk exercise
Number of subjects: 29
Study 24986094 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (400 µg, single inhaled supra-therapeutic dose)
Number of subjects: 73
Study 24986094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24986094 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 73
Study 22818144 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg PD‐0299685 daily
Number of subjects: 161
Study 22818144 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg PD‐0299685 daily
Number of subjects: 161
Study 22818144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 19070833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage (fFN-positive)
Number of subjects: 0
Study 19070833 — intervention group
Group type: COMPARATOR
Intervention: No cerclage (fFN-positive)
Number of subjects: 0
Study 19070833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage (fFN-negative)
Number of subjects: 0
Study 19070833 — intervention group
Group type: COMPARATOR
Intervention: No cerclage (fFN-negative)
Number of subjects: 0
Study 17334512 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX 4016 (800 mg b.i.d.)
Number of subjects: 44
Study 17334512 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg o.d.)
Number of subjects: 44
Study 15455743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with coronally positioned flap
Number of subjects: 13
Study 15455743 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap alone (CPF)
Number of subjects: 13
Study 11683739 — intervention group
Group type: COMPARATOR
Intervention: DL (dilator technique)
Number of subjects: 58
Study 11683739 — intervention group
Group type: EXPERIMENTAL
Intervention: ND (no dilator technique)
Number of subjects: 58
Study 11683739 — intervention group
Group type: EXPERIMENTAL
Intervention: DL (dilator technique) and ND (no dilator technique)
Number of subjects: 58
Study 10030463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatebradine 10 mg i.v. (n = 24)
Number of subjects: 36
Study 10030463 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (n = 12)
Number of subjects: 36
Study 8049639 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin/mineral supplementation
Number of subjects: 3318
Study 8049639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3318
Study 3281637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 74
Study 3281637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31173662 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training intervention
Number of subjects: 3435
Study 31173662 — intervention group
Group type: COMPARATOR
Intervention: Teacher training plus parental-awareness meetings
Number of subjects: 3435
Study 28917367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of hatha yoga classes
Number of subjects: 50
Study 28917367 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 50
Study 25313670 — intervention group
Group type: EXPERIMENTAL
Intervention: HAP-focused physician
Number of subjects: 0
Study 25313670 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-focused physician
Number of subjects: 0
Study 23933066 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and endurance training performed twice a week (SE2, n=12)
Number of subjects: 24
Study 23933066 — intervention group
Group type: COMPARATOR
Intervention: Strength and endurance training performed three times per week (SE3, n=12)
Number of subjects: 24
Study 20692104 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40
Study 20692104 — intervention group
Group type: COMPARATOR
Intervention: Placebo TSST
Number of subjects: 40
Study 19047288 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 19047288 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 16884320 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 10-240 mg
Number of subjects: 120
Study 15633321 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium oxalate gel
Number of subjects: 15
Study 15633321 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 15
Study 10564141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (NP) infusion (0.3-1.0 microgram.kg(‐1).min(‐1))
Number of subjects: 16
Study 10564141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment without extraction
Number of subjects: 148
Study 8638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction decisions
Number of subjects: 148
Study 8638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for extraction
Number of subjects: 148
Study 8638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reasons for extraction
Number of subjects: 148
Study 8638581 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary considerations
Number of subjects: 148
Study 1666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy
Number of subjects: 848
Study 1666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted radical mastectomy
Number of subjects: 848
Study 1666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patey radical mastectomy
Number of subjects: 848
Study 1666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Madden radical mastectomy
Number of subjects: 848
Study 1666275 — intervention group
Group type: COMPARATOR
Intervention: All surgical treatments
Number of subjects: 848
Study 6339312 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg/day, increased to 160 mg/day if no response)
Number of subjects: 40
Study 6339312 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (150 mg/day, increased to 300 mg/day if no response)
Number of subjects: 40
Study 6339312 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (after furosemide failure)
Number of subjects: 40
Study 31415797 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy × 5
Number of subjects: 203
Study 31415797 — intervention group
Group type: COMPARATOR
Intervention: 3 Gy × 10
Number of subjects: 203
Study 28825423 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXB-A 150 mg (extended-release formulation) administered four times daily for 1 month
Number of subjects: 80
Study 28825423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 27108818 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2mg/kg)
Number of subjects: 100
Study 27108818 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3mg/kg)
Number of subjects: 100
Study 23689047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 4-5 L/min
Number of subjects: 9
Study 23689047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 6-7 L/min
Number of subjects: 9
Study 23689047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-driven nebulization (ODN) at 8-9 L/min
Number of subjects: 9
Study 22300505 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse practitioner intervention (up to three home visits and two telephone calls)
Number of subjects: 199
Study 22300505 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard medical care including access to case management services)
Number of subjects: 199
Study 21086650 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 21086650 — intervention group
Group type: COMPARATOR
Intervention: Glucose-salt solutions
Number of subjects: 0
Study 18515672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-derived peak diastolic gradient
Number of subjects: 38
Study 18515672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-derived mid diastolic gradient
Number of subjects: 38
Study 18515672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-derived end diastolic gradient
Number of subjects: 38
Study 18515672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler pulmonary artery diastolic gradients
Number of subjects: 38
Study 15842989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle, seated exercise program
Number of subjects: 82
Study 15842989 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study 12848774 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine 200 mg
Number of subjects: 15
Study 12848774 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine 200 mg every 8 h on day 32
Number of subjects: 15
Study 12848774 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone 90 mg
Number of subjects: 15
Study 12848774 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone 90 mg after retigabine administration
Number of subjects: 15
Study 12848774 — intervention group
Group type: EXPERIMENTAL
Intervention: AWD21‐360 (metabolite of retigabine)
Number of subjects: 15
Study 10493336 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-component acellular pertussis vaccine
Number of subjects: 366
Study 10493336 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 366
Study 8902922 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (2 g daily)
Number of subjects: 10
Study 8902922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1988239 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with glipizide (5 mg)
Number of subjects: 8
Study 1988239 — intervention group
Group type: COMPARATOR
Intervention: Control (water) with glipizide (5 mg)
Number of subjects: 8
Study 6294732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sincalide
Number of subjects: 35
Study 6294732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sincalide
Number of subjects: 35
Study 6294732 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 35
Study 31864163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapies (specific types not mentioned)
Number of subjects: 1051
Study 30108163 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (5 g t.i.d.)
Number of subjects: 106
Study 30108163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 28547078 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline as buccal and lingual infiltration
Number of subjects: 100
Study 28547078 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with 1:80,000 adrenaline using classic direct inferior alveolar nerve block
Number of subjects: 100
Study 26903288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (PaCO2 45-55mmHg)
Number of subjects: 7
Study 26903288 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (PaCO2 35-45mmHg)
Number of subjects: 7
Study 23979151 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antibiotics tested (excluding imipenem)
Number of subjects: 19756
Study 23979151 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 19756
Study 23979151 — intervention group
Group type: COMPARATOR
Intervention: Geographic regions (North Europe)
Number of subjects: 19756
Study 23979151 — intervention group
Group type: COMPARATOR
Intervention: Asia
Number of subjects: 19756
Study 21789502 — intervention group
Group type: EXPERIMENTAL
Intervention: 512 Psychological Intervention Model (512 PIM)
Number of subjects: 2368
Study 21789502 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 2368
Study 21789502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2368
Study 19682170 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO) administered in escalating doses of 5, 10, 15, and 20 microg/min
Number of subjects: 112
Study 19682170 — intervention group
Group type: COMPARATOR
Intervention: Rapid atrial pacing (RAP)
Number of subjects: 112
Study 19682170 — intervention group
Group type: COMPARATOR
Intervention: Cardioversion for persistent AF after ablation
Number of subjects: 112
Study 18845996 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 60 mg/m² every 3 weeks
Number of subjects: 509
Study 18845996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 4 weeks
Number of subjects: 509
Study 12417546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary veins (PVs) in patients with AF
Number of subjects: 48
Study 12417546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing in PVs in patients with AF
Number of subjects: 48
Study 12417546 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary veins (PVs) in control patients
Number of subjects: 48
Study 10357241 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressures (COP's) in patients with bilateral ankle oedema
Number of subjects: 0
Study 10357241 — intervention group
Group type: COMPARATOR
Intervention: Colloid osmotic pressures (COP's) in healthy volunteers
Number of subjects: 0
Study 10357241 — intervention group
Group type: COMPARATOR
Intervention: Colloid osmotic pressures (COP's) in treated hypertensives
Number of subjects: 0
Study 8455319 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of all substrates with bolus‐based intermittent infusions during 60 minutes six times per day (24 hours)
Number of subjects: 0
Study 8455319 — intervention group
Group type: COMPARATOR
Intervention: Sequential infusion of fat plus amino acids at a constant rate over 12 hours during daytime followed by glucose infusion at a constant rate for 12 hours during nighttime
Number of subjects: 0
Study 8455319 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous infusion of all substrates at a constant rate over 24 hours
Number of subjects: 0
Study 3510410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg/m2 for doxorubicin, 95 mg/m2 for cis-platinum) administered intravenously 15 min prior to chemotherapy
Number of subjects: 27
Study 29758154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric rechargeable toothbrush (Oral-B® PRO 1000, D16U)
Number of subjects: 150
Study 29758154 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush (Philips Sonicare® Diamond Clean Toothbrush with AdaptiveClean brush head)
Number of subjects: 150
Study 27179693 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20-Hz) targeting the left temporoparietal cortex, 4 sessions over 2 days (total 10,400 stimulations)
Number of subjects: 30
Study 27179693 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 26058585 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose theophylline (Uniphyllin MR 200 mg tablets)
Number of subjects: 1424
Study 26058585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1424
Study 23666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 80
Study 23666275 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 80
Study 21228269 — intervention group
Group type: EXPERIMENTAL
Intervention: CD36 SNPs (rs1984112, rs1527479, rs7755, rs1527483) in SU.VI.MAX cohort
Number of subjects: 1614
Study 21228269 — intervention group
Group type: EXPERIMENTAL
Intervention: CD36 SNPs (rs1984112, rs1761667, rs1527479) in HELENA Study
Number of subjects: 1614
Study 21228269 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with fasting serum triglycerides and long‐chain polyunsaturated fatty acids
Number of subjects: 1614
Study 18155202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART cycle screening with saline infusion sonohysterography
Number of subjects: 0
Study 18155202 — intervention group
Group type: COMPARATOR
Intervention: Normal endometrial lining
Number of subjects: 0
Study 16580384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg) as a spray
Number of subjects: 233
Study 16580384 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg/0.5 mg) as a capsule
Number of subjects: 233
Study 12960704 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation training
Number of subjects: 50
Study 12960704 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study 10666351 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9461
Study 10666351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9461
Study 9586788 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 23
Study 9586788 — intervention group
Group type: COMPARATOR
Intervention: Oral, semielemental diet (SED)
Number of subjects: 23
Study 7921321 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey recruitment
Number of subjects: 357
Study 7921321 — intervention group
Group type: COMPARATOR
Intervention: Community media campaign
Number of subjects: 357
Study 3041336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilactin (hydroxypropyl cellulose film former)
Number of subjects: 32
Study 3041336 — intervention group
Group type: COMPARATOR
Intervention: Widely available topical preparation
Number of subjects: 32
Study 31693197 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) pattern with Jp ≥2 mm
Number of subjects: 17901
Study 31693197 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) pattern with Jp ≥2 mm in Hispanic patients
Number of subjects: 17901
Study 31693197 — intervention group
Group type: COMPARATOR
Intervention: Early repolarization (ER) pattern with Jp ≥1 mm
Number of subjects: 17901
Study 29843761 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment for 10 days in addition to routine pharmacological treatment.
Number of subjects: 150
Study 29843761 — intervention group
Group type: COMPARATOR
Intervention: Routine pharmacological treatment alone (Control group).
Number of subjects: 150
Study 28241354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (n=60)
Number of subjects: 120
Study 28241354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=60)
Number of subjects: 120
Study 26232375 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (1 or 2 mg/kg Q2W or 2 or 3 mg/kg Q4W)
Number of subjects: 48
Study 26232375 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 48
Study 26232375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24002601 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab SC 1400 mg
Number of subjects: 0
Study 24002601 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC 600 mg
Number of subjects: 0
Study 24002601 — intervention group
Group type: COMPARATOR
Intervention: Rituximab SC
Number of subjects: 0
Study 24002601 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab SC
Number of subjects: 0
Study 21917894 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) monotherapy
Number of subjects: 0
Study 19274983 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (prednisolone)
Number of subjects: 513
Study 19274983 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month corticosteroid regimen
Number of subjects: 513
Study 19274983 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 month corticosteroid regimen
Number of subjects: 513
Study 19274983 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 513
Study 17046383 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (no additional medication)
Number of subjects: 330
Study 17046383 — intervention group
Group type: COMPARATOR
Intervention: Sublingual lorazepam (0.5 to 1 mg, approximately 20 min preoperatively)
Number of subjects: 330
Study 17046383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation (fentanyl and midazolam, doses from 50 to 125 microg of fentanyl and 1‐2 mg of midazolam)
Number of subjects: 330
Study 12632336 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorocarbon-induced lung growth (PILG)
Number of subjects: 13
Study 12632336 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV/control)
Number of subjects: 13
Study 10955049 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prompting methods (either preference, food category, or visual)
Number of subjects: 96
Study 10955049 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific prompting for food category
Number of subjects: 96
Study 8831520 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 61
Study 8831520 — intervention group
Group type: COMPARATOR
Intervention: Handsewn closure
Number of subjects: 61
Study 1546818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.8 mg for <14 kg, 1.2 mg for ≥14 kg)
Number of subjects: 121
Study 1546818 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 121
Study 3886404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine + prazepam
Number of subjects: 50
Study 3886404 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine + placebo
Number of subjects: 50